GlobeNewswire Inc.··NaCogent Biosciences Presents Expanded SUMMIT Trial Results for Bezuclastinib at 2026 AAAAI Meeting
Cogent Biosciences presented expanded SUMMIT trial data showing bezuclastinib achieved significant symptom reduction and tryptase normalization in systemic mastocytosis patients, supporting its FDA regulatory applications.
COGTdisease modificationclinical results